Obesity is a chronic disease whose effects are growing daily.The effects of the disease spread through the entire body, making it one of the leading causes of death internationally.Recent drug discoveries have found new pathways in the gastrointestinal tract that can be targeted to promote weight loss and reduce the effects of obesity on the population.This is a novel addition to the current weight loss treatments.This paper will review the biological mechanisms behind Glucagon-like peptide-1 (GLP-1) based therapies and their effects on obesity treatment.We will begin by discussing the emergent need to research the field of obesity through a global health lens.We will discuss the economic impacts as well as the causes and effects of this disease.Then, we will discuss the current treatment landscape, addressing any disparities and drawbacks with current treatment options.Following this the paper will go in-depth about different gastrointestinal hormones, such as GLP-1, GIP, and Glucagon, being used to treat this chronic disease.This article is intended to give an overview of GLP-1-based therapies and the effect it has on various biological activities relating to obesity.